Skip to main content
. 2020 May 12;8:230. doi: 10.3389/fped.2020.00230

Table 1.

ELGAN study birth characteristics collected in 2002–2004 and ancillary kidney study visit data collected in 2017–2019 by composite kidney outcome (microalbuminuria, elevated blood pressure, and/or abnormal kidney mass by ultrasound*).

Characteristics Total
(n = 42)
Composite kidney outcome Composite kidney outcome P-value***
Absent
(n = 21)
Present
(n = 21)
Birth characteristics collected 2002–2004
Gestational age at birth (weeks), mean(SD) 25.7 ± 1.1 25.5 ± 1.0 26.0 ± 1.1 0.13
Birth weight (grams), mean(SD) 770.0 ± 173.1 807.2 ± 190.3 732.8 ± 149.3 0.22
Delivery resuscitation interventions, n (%) 0.94
Missing 1 (2.4%) 0 (0.0%) 1 (4.8%)
Positive pressure ventilation 5 (11.9%) 3 (14.3%) 2 (9.5%)
Intubation 33 (78.6%) 16 (76.2%) 17 (81.0%)
Compressions 1 (2.4%) 1 (4.8%) 0 (0.00%)
Epinephrine 2 (4.8%) 1 (4.8%) 1 (4.8%)
APGAR 1 min, md(IQR) 4.5 (2.0, 7.0) 5.00 (2.0, 6.0) 4.0 (3.0, 7.0) 0.45
APGAR 5 min, md(IQR) 7.0 (5.0, 8.0) 7.0 (5.0, 8.0) 7.00 (6.00, 8.00) 0.56
Neonatal indomethacin exposure, n (%) 19 (45.2%) 11 (52.4%) 8 (38.1%) 0.35
Neonatal sepsis in 1st month, n (%) 0.70
Missing 1 (2.4%) 1 (4.8%) 0 (0.0%)
No 31 (73.8%) 16 (76.2%) 15 (71.4%)
Yes 10 (23.8%) 4 (19.1%) 6 (28.57%)
Mechanical ventilator days, md (IQR) 19.0 (5.0, 28.0) 26.5 (8.0, 28.0) 14.0 (4.0, 28.0) 0.31
Urine output (ml/kg/hr), mean(SD) δ 1.6 ±1.1 1.7 ± 1.3 1.4 ± 0.9 0.11
Any inflammatory proteins >75th percentile, n (%)¥ 26 (61.9%) 12 (57.1%) 14 (66.7%) 0.75
Duration of NICU course (weeks), mean(SD) 12.7 ± 6.9 14.2 ± 8.3 11.1 ± 4.8 0.06
Lowest MAP(mmHg), med (IQR) 23.0 (19.0, 27.0) 23.0 (21.0, 29.0) 20.0 (17.0, 25.0) 0.10
Hypotension, n (%) 16 (38.1%) 5 (23.8%) 11 (52.4%) 0.0236
Use of vasopressors in first 14 days of life, n (%) 21 (50%) 8 (38.1%) 13 (61.9%) 0.35
Any patent ductus arteriosus, n (%) 28 (66.7%) 12 (57.1%) 16 (76.2%) 0.21
# of Doses of methylxanthine in first 28 days, md(IQR) 10.0 (0.0, 24.0) 5 (0.0, 22.0) 12.0 (2.0, 25.0) 0.11
Growth velocity (g/kg/day), mean(SD)** 24.6 ± 8.6 24.7 ± 8.7 24.6 ± 8.7 0.64
Gestational age at discharge, mean(SD) 38.4 ± 6.5 39.7 ± 7.9 37.1 ± 4.3 0.09
Ancillary 15-year old renal study visit characteristics collected 2017–2019
Age (years), med (IQR) 15.0 (15.0, 15.3) 15.0 (15.0, 15.1) 15.1 (15.0, 15.4) 0.47
Males, n (%) 25 (59.5%) 10 (47.6%) 15 (71.4%) 0.35
Race, n (%) 0.67
Caucasian 22 (52.4%) 11 (52.4%) 11 (52.4%)
African-American 18 (42.9%) 9 (42.9%) 9 (42.9%)
Other 2 (4.8%) 1 (4.8%) 1 (4.8%)
BMI >85th percentile, n (%) 22 (52.4%) 10 (47.6%) 12 (57.1%) 0.53
BMI percentile, mean(SD) 70.7 ± 30.2 70.2 ± 29.8 71.1 ± 31.0 0.92
Elevated blood pressure (>120/80 mmHg), n (%) 14 (33.3%) 0 (0.0%) 14 (58.3%)
Systolic blood pressure (mmHg), med (IQR) 115.8 (109.0, 121.5) 111.0 (107.0, 116.0) 121.0 (111.0, 125.5) 0.0021
Diastolic blood pressure (mmHg), med (IQR) 70.0 (64.0, 76.0) 69.5 (64.0, 73.0) 71.0 (66.0, 81.0) 0.25
Renal hypoplasia*, n (%) 6 (14.3%) 0 (0.0%) 6 (28.6%)
Right renal length (cm), mean(SD) 9.4 ± 0.7 9.4 ± 0.9 9.3 ± 0.6 0.12
Left renal length (cm), mean(SD) 9.7 ± 0.9 9.8 ± 1.0 9.6 ± 0.8 0.09
Microalbuminuria (>30μg/g), n (%) 5 (11.9%) 0 (0.0%) 5 (23.8%)
Urine albumin/creatinine (μg/g), md(IQR) 7.6 (5.4, 14.9) 6.7 (4.6, 11.8) 12.5 (5.9, 30.7) 0.0253
*

Abnormal renal mass defined by body surface area related renal volume below mean and standard deviation.

δ

Urine output in the first 12 h of life.

¥

Inflammatory proteins measured at birth include CRP, IGF, EPO, VEGFR, IL-8, TNF-α, IL-6, and IL-1β.

**

Growth Velocity = [(Discharge weight-birthweight)/birthweight]/Length of Stay (18).

#

lowest MAP in lowest quartile for gestational age.

***

P-values were calculated by Chi-square and Fisher's exact test of significance for categorical independent variables, Mannz–Whitney U-test for non-parametric interval independent variables, t-test of significance used for interval independent variables.